-+ 0.00%
-+ 0.00%
-+ 0.00%

EUROPEAN COMMISSION APPROVES KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AS PERIOPERATIVE TREATMENT FOR ADULTS WITH RESECTABLE MUSCLE-INVASIVE BLADDER CANCER (MIBC)

Reuters·10/21/2026 10:45:00

Please log in to view news